COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF
Provided are a compound of formula 0, a stereoisomer thereof, a tautomer thereof, a geometric isomer thereof, an enantiomer thereof, a diastereomer thereof, a racemate thereof, a polymorph thereof, a solvate thereof, a hydrate thereof, an N-oxide thereof, an isotopically labeled compound thereof, a metabolite thereof, an ester thereof, a prodrug thereof, and a pharmaceutically acceptable salt thereof. In formula 0, ring B is a 5- to 10-membered spiro ring or a 5- to 10-membered spiro heterocyclic ring. The 5- to 10-membered spiro ring and the 5- to 10-membered spiro heterocyclic ring are optionally substituted with 1-5 R1F. The compound can significantly weaken the integrated stress response (ISR) of cells and activate the activity of eIF2B, so that proteins in the cells tend to be synthesized normally. <img file="PCTCN2023111229-isre-I000011.jpg" he="22.22" img-content="drawing" img-format="jpg" inline="yes" orientation="portrait" wi="61.38"/>.
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 15. Feb. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
CAO BIN [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-02-15, Last update posted on www.tib.eu: 2024-03-20, Last updated: 2024-03-29 |
|---|
| Patentnummer: |
WO2024032501 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA001454153 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA001454153 | ||
| 003 | DE-627 | ||
| 005 | 20240329160327.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240322s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA001454153 | ||
| 035 | |a (EPA)WO2024032501 | ||
| 035 | |a (EPA)89850755 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a CAO BIN |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-02-15, Last update posted on www.tib.eu: 2024-03-20, Last updated: 2024-03-29 | ||
| 520 | |a Provided are a compound of formula 0, a stereoisomer thereof, a tautomer thereof, a geometric isomer thereof, an enantiomer thereof, a diastereomer thereof, a racemate thereof, a polymorph thereof, a solvate thereof, a hydrate thereof, an N-oxide thereof, an isotopically labeled compound thereof, a metabolite thereof, an ester thereof, a prodrug thereof, and a pharmaceutically acceptable salt thereof. In formula 0, ring B is a 5- to 10-membered spiro ring or a 5- to 10-membered spiro heterocyclic ring. The 5- to 10-membered spiro ring and the 5- to 10-membered spiro heterocyclic ring are optionally substituted with 1-5 R1F. The compound can significantly weaken the integrated stress response (ISR) of cells and activate the activity of eIF2B, so that proteins in the cells tend to be synthesized normally. <img file="PCTCN2023111229-isre-I000011.jpg" he="22.22" img-content="drawing" img-format="jpg" inline="yes" orientation="portrait" wi="61.38"/> | ||
| 650 | 4 | |a C07D: Heterocyclic compounds (macromolecular compounds c08) | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a ZHAO LIYU |4 aut | |
| 700 | 0 | |a DOU GUOSHENG |4 aut | |
| 700 | 0 | |a LU SIZHU |4 aut | |
| 700 | 0 | |a YANG JUN |4 aut | |
| 700 | 0 | |a CHEN ZHAOQIANG |4 aut | |
| 700 | 0 | |a ZHANG QIHUA |4 aut | |
| 700 | 0 | |a WANG SHAOHUI |4 aut | |
| 700 | 0 | |a CHEN BIN |4 aut | |
| 700 | 0 | |a ZHANG PEIYU |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 15. Feb. |
| 773 | 1 | 8 | |g year:2024 |g day:15 |g month:02 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/89850755/publication/WO2024032501A1?q=WO2024032501 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 15 |c 02 | ||